Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer cells in the phase\u00e2 $ 3 FLARE CRC test

.Competing interests.S.K.: Sell and Other Possession Passions: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Function: AbbVie, Amal Rehabs, AstraZeneca/MedImmune, Bayer Wellness, Bicara Therapeutics, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Undertaking BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Rock Health Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Study Funding: Amgen (Inst), Collection BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health And Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Job: In The Past Pfizer. Stock and Other Possession Enthusiasms: Pfizer. J.P.: Work: Formerly Pfizer. Inventory and Various Other Ownership Claims: Pfizer. F.C.: Consulting or Advisory Function: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Study Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Task: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Research Study Financing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or even Advisory Task: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or Advisory Task: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Med), Zymeworks. Investigation Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Research Study Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Job: Pfizer. Sell as well as Various Other Possession Interests: Pfizer. X.Z.: Work: Pfizer. Stock and Various Other Ownership Stakes: Pfizer. Patents, Nobilities, Various Other Trademark: Johns Hopkins University. P.H.: Employment: Pfizer. Sell and also Various Other Ownership Stakes: Pfizer. T.X.: Work: Pfizer. Inventory and also Other Possession Claims: Pfizer. R.Y.: Consulting or even Advisory Function: Range BioPharma/Pfizer, Mirati Therapies, Zai Lab, Amgen. Study Backing: Collection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Rehab (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Job: Variety BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapeutics, MSD, NeoPhore, Novartis, Ona Therapies, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Therapeutics, TheraMyc. Other Partnership: Amgen, Assortment Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Research UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Opposite el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Principle for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education And Learning Source, Sanofi-Aventis, Servier, Taiho Pharmaceutical.